. . "Dimethyl-fumar\u00E1t v l\u00E9\u010Db\u011B relabuj\u00EDc\u00ED-remituj\u00EDc\u00ED formy roztrou\u0161en\u00E9 skler\u00F3zy" . "1"^^ . . . "1"^^ . . . "[49C536DFFEE6]" . . "4" . "RIV/00216208:11130/14:10293487" . "15" . "Dimethyl-fumar\u00E1t v l\u00E9\u010Db\u011B relabuj\u00EDc\u00ED-remituj\u00EDc\u00ED formy roztrou\u0161en\u00E9 skler\u00F3zy"@cs . "RIV/00216208:11130/14:10293487!RIV15-MSM-11130___" . "Dimethyl-fumar\u00E1t v l\u00E9\u010Db\u011B relabuj\u00EDc\u00ED-remituj\u00EDc\u00ED formy roztrou\u0161en\u00E9 skler\u00F3zy"@cs . . . . "Dimethyl-fumar\u00E1t v l\u00E9\u010Db\u011B relabuj\u00EDc\u00ED-remituj\u00EDc\u00ED formy roztrou\u0161en\u00E9 skler\u00F3zy" . . "http://www.neurologiepropraxi.cz/pdfs/neu/2014/04/07.pdf" . . "Neurologie pro praxi" . "5"^^ . "CZ - \u010Cesk\u00E1 republika" . "Meluz\u00EDnov\u00E1, Eva" . "11130" . . "I" . "1213-1814" . . "Dimethyl-fumarate in treating relapsing-remitting multiple sclerosis"@en . . "Roztrou\u0161en\u00E1 skler\u00F3za (RS) je chronick\u00E9 z\u00E1n\u011Btliv\u00E9 a neurodegenerativn\u00ED onemocn\u011Bn\u00ED centr\u00E1ln\u00EDho nervov\u00E9ho syst\u00E9mu (CNS), k neurodegeneraci doch\u00E1z\u00ED ji\u017E od za\u010D\u00E1tku onemocn\u011Bn\u00ED. P\u0159i \u010Dasn\u00E9m pou\u017Eit\u00ED l\u00E9\u010Dby je mo\u017En\u00E9 cel\u00FD imunopatologick\u00FD proces zpomalit. Proto je terapie zahajov\u00E1na nejl\u00E9pe hned po prvn\u00EDm p\u0159\u00EDznaku onemocn\u011Bn\u00ED nebo ve stadiu relabuj\u00EDc\u00ED-remituj\u00EDc\u00ED RS (RR-RS). V takov\u00E9m p\u0159\u00EDpad\u011B jsou pou\u017E\u00EDv\u00E1ny l\u00E9ky prvn\u00ED volby (Disease Modifying Drugs - DMD). U pacient\u016F s nedostate\u010Dn\u00FDm efektem t\u00E9to terapie je nutn\u00E1 eskalace. K tomuto \u00FA\u010Delu je k dispozici bu\u010F intraven\u00F3zn\u011B pod\u00E1van\u00FD natalizumab nebo peror\u00E1ln\u011B pod\u00E1van\u00FD fingolimod. Zat\u00EDm \u017E\u00E1dn\u00FD z v\u00FD\u0161e uveden\u00FDch l\u00E9k\u016F nespl\u0148uje optim\u00E1ln\u00ED kombinaci \u00FA\u010Dinnosti s dobrou toleranc\u00ED, bezpe\u010Dnost\u00ED a ovlivn\u011Bn\u00EDm jak z\u00E1n\u011Btu, tak procesu neurodegenerace. Zd\u00E1 se, \u017Ee nejbl\u00ED\u017Ee t\u011Bmto po\u017Eadavk\u016Fm by mohl b\u00FDt dimethyl-fumar\u00E1t (Tecfidera(R)), kter\u00FD byl 3. 2. 2014 registrov\u00E1n pro l\u00E9\u010Dbu RR-RS v EU. V\u00FDsledky pr\u00E1v\u011B prob\u00EDhaj\u00EDc\u00EDch poregistra\u010Dn\u00EDch klinick\u00FDch studi\u00ED potvrd\u00ED, zda m\u00E1 dimethyl-fumar\u00E1t p\u0159edpokl\u00E1dan\u00FD potenci\u00E1l b\u00FDt za\u0159azen mezi l\u00E9ky prvn\u00ED volby RR-RS."@cs . . "Dimethyl-fumarate in treating relapsing-remitting multiple sclerosis"@en . "11598" . "DMD; first-choice drugs; BG-12; dimethyl fumarate; neuroprotection; neurodegeneration; multiple sclerosis"@en . "Roztrou\u0161en\u00E1 skler\u00F3za (RS) je chronick\u00E9 z\u00E1n\u011Btliv\u00E9 a neurodegenerativn\u00ED onemocn\u011Bn\u00ED centr\u00E1ln\u00EDho nervov\u00E9ho syst\u00E9mu (CNS), k neurodegeneraci doch\u00E1z\u00ED ji\u017E od za\u010D\u00E1tku onemocn\u011Bn\u00ED. P\u0159i \u010Dasn\u00E9m pou\u017Eit\u00ED l\u00E9\u010Dby je mo\u017En\u00E9 cel\u00FD imunopatologick\u00FD proces zpomalit. Proto je terapie zahajov\u00E1na nejl\u00E9pe hned po prvn\u00EDm p\u0159\u00EDznaku onemocn\u011Bn\u00ED nebo ve stadiu relabuj\u00EDc\u00ED-remituj\u00EDc\u00ED RS (RR-RS). V takov\u00E9m p\u0159\u00EDpad\u011B jsou pou\u017E\u00EDv\u00E1ny l\u00E9ky prvn\u00ED volby (Disease Modifying Drugs - DMD). U pacient\u016F s nedostate\u010Dn\u00FDm efektem t\u00E9to terapie je nutn\u00E1 eskalace. K tomuto \u00FA\u010Delu je k dispozici bu\u010F intraven\u00F3zn\u011B pod\u00E1van\u00FD natalizumab nebo peror\u00E1ln\u011B pod\u00E1van\u00FD fingolimod. Zat\u00EDm \u017E\u00E1dn\u00FD z v\u00FD\u0161e uveden\u00FDch l\u00E9k\u016F nespl\u0148uje optim\u00E1ln\u00ED kombinaci \u00FA\u010Dinnosti s dobrou toleranc\u00ED, bezpe\u010Dnost\u00ED a ovlivn\u011Bn\u00EDm jak z\u00E1n\u011Btu, tak procesu neurodegenerace. Zd\u00E1 se, \u017Ee nejbl\u00ED\u017Ee t\u011Bmto po\u017Eadavk\u016Fm by mohl b\u00FDt dimethyl-fumar\u00E1t (Tecfidera(R)), kter\u00FD byl 3. 2. 2014 registrov\u00E1n pro l\u00E9\u010Dbu RR-RS v EU. V\u00FDsledky pr\u00E1v\u011B prob\u00EDhaj\u00EDc\u00EDch poregistra\u010Dn\u00EDch klinick\u00FDch studi\u00ED potvrd\u00ED, zda m\u00E1 dimethyl-fumar\u00E1t p\u0159edpokl\u00E1dan\u00FD potenci\u00E1l b\u00FDt za\u0159azen mezi l\u00E9ky prvn\u00ED volby RR-RS." . . "Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS), with neurodegeneration occurring from the very onset of the disease. With timely treatment, it is possible to slow down the whole immunopathological process. Therefore, treatment is best initiated at the first sign of disease or in the stage of relapsing-remitting MS (RRMS). In such a case, first-choice drugs are used (disease-modifying drugs - DMD). Escalation is required in patients with an insufficient effect of this treatment. For this purpose, either intravenous natalizumab or oral fingolimod are available. So far, none of the above-mentioned drugs has been shown to provide the optimal combination of efficacy with good tolerance and safety while targeting both the inflammation and the process of neurodegeneration. Dimethyl-fumarate (Tecfidera(R)), which was registered for the treatment of RRMS in the EU on 3rd February 2014, seems to meet these requirements most closely. The results of the ongoing postregistered clinical trials confirm if the dimethyl fumarate is anticipated to have the potential to be classified as the drug of first choice in patients with RRMS."@en . .